Clinical Trials Directory

Trials / Completed

CompletedNCT00204490

Soy Isoflavones and Breast Cancer Risk Reduction

Mammographic Density and Soy Isoflavones

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
197 (actual)
Sponsor
The University of Texas Medical Branch, Galveston · Academic / Other
Sex
Female
Age
30 Years – 42 Years
Healthy volunteers
Accepted

Summary

Soy consumption has been associated with reduced risk for developing breast cancer. Soy contains isoflavones which are weak estrogens. The roles of soy isoflavones in reducing breast cancer risk are currently unclear. Breast density has been considered as a breast cancer risk marker. We hypothesize that because isoflavones have estrogen-like activities, breast density and possibly bone density will be lower in women on soy-isoflavones.

Detailed description

This is a randomized, double-blind study, with two arms and 100 women in each arm. Premenopausal women will be recruited and randomly allocated to take one of the two different dietary supplements in pills daily for 2 years. The two supplements are soy isoflavones (treatment) and placebo (carbohydrates). Both treatment and placebo pills will contain multi-vitamins and minerals. Multiple blood, urine, and breast fluid samples will be obtained before and during the dietary supplement periods and analyzed for biomarkers of breast cancer risk. At baseline and after the intervention period, breast density and bone density will be assessed by radiologic techniques. The efficacy of the dietary intervention will be determined by comparing mean changes of serum markers for breast cancer risk,dense breast tissue, and bone mineral density over the two year dietary intervention period in the two supplement groups with adjustment for baseline values and individual patient characteristics of interest. We predict that 2 years of soy isoflavone supplement will reduce breast density, which may be explained by individual changes in serum markers of breast cancer risk.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTisoflavonessoy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
DIETARY_SUPPLEMENTcarbohydratecarbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.

Timeline

Start date
2004-04-01
Primary completion
2012-12-10
Completion
2023-05-31
First posted
2005-09-20
Last updated
2024-05-16
Results posted
2024-05-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00204490. Inclusion in this directory is not an endorsement.